A Study of LY4006896
Phase 1
127
about 3 years
30–85
11 sites in CA, FL, MI +2
About this study
This trial is testing a treatment called LY4006896 in people with Parkinson's disease and healthy adults. The goal is to see if this treatment is safe and how it works in the body.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take LY4006896
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of Participants with One or More SAEs Part B, Number of Participants with One or More Serious Adverse Event(s) (SAEs) Part A, Number of Participants with One or More TEAEs Part B, Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs) Part A
Secondary: PK: AUC of LY4006896 ARC-Associated Antisense Part B, PK: Area Under the Concentration versus Time Curve (AUC) of LY4006896 ARC-Associated Antisense Part A, PK: Cmax of LY4006896 ARC-Associated Antisense Part B, Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4006896 ARC-Associated Antisense Part A
Neurology